Stock 688321 SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Shenzhen Chipscreen Biosciences Co., Ltd.

Equities

688321

CNE100003LW0

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
21.91 CNY +0.55% Intraday chart for Shenzhen Chipscreen Biosciences Co., Ltd. +6.00% -0.18%
Apr. 28 Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 22 Chipscreen Biosciences Offers Sell-Back Option for Microchip Convertible Bond Holders MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Chipscreen Biosciences Offers Sell-Back Option for Microchip Convertible Bond Holders
MT
Tranche Update on Shenzhen Chipscreen Biosciences Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.
CI
Shenzhen Chipscreen Biosciences Co., Ltd. commences an Equity Buyback Plan for CNY 15 million worth of its shares, under the authorization approved on February 22, 2024.
CI
Shenzhen Chipscreen Biosciences Co., Ltd. Announces Positive Results from Phase II Clinical Trial (CGZ203 Study) of Chiglitazar Monotherapy for Non-Alalcoholic Steatohepatitis
CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Chipscreen Biosciences' New Production Line Passes Regulatory Inspection
MT
Chipscreen Biosciences Gets Regulatory Nod for China Clinical Trial of Psoriasis Drug
MT
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Shenzhen Chipscreen Biosciences Co., Ltd.(XSSC:688321) added to S&P Global BMI Index
CI
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Chinese Drug Regulator to Prioritize Shenzhen Chipscreen Biosciences' Application for Chidamide Tablets
MT
Shenzhen Chipscreen Biosciences Gets Nod for Tumor Drug Trial
MT
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Biocytogen's Subsidiary Eucure Biopharma and Chipscreen Biosciences Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008
AQ
Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008
BU
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Shenzhen Chipscreen Biosciences' Diabetes Drug Placed in 2022 Chinese Drug Catalogue
MT
Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Shenzhen Chipscreen Biosciences Co., Ltd. announced that it expects to receive CNY 260 million in funding
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 688321 Stock
  4. News Shenzhen Chipscreen Biosciences Co., Ltd.